Japan

BMI View: Japan's medical device market is an attractive proposition to local and foreign companies. Sales have grown consistently over the past decade and we forecast sustained expansion... 2012-01-23

BMI View: Daiichi Sankyo needs to increase its exposure to both emerging markets and developed states. Despite the acceleration of Europe's sovereign debt crisis and the inevitability... 2011-11-02

BMI View: Japan's pharmaceutical regulatory regime admirably addresses the needs and concerns of the three major industry stakeholders - patients, payers and pharmaceutical companies... 2011-10-28

BMI Core View: Non-healthcare companies, particularly technology firms, will increasingly enter the medical services sector. Companies see healthcare as a sustainable and expanding... 2011-08-15

BMI View: Despite Astellas Pharma's minimal exposure to generic drug competition and its optimistic forecast going into 2015, BMI is cautious of a company that has seen almost no organic... 2011-08-02

BMI View: Traditionally, multinational drugmakers have maintained high revenue streams in developed markets through the sale of high-value patented medicines. While it is our view that... 2011-07-01

BMI View: The Japanese government's appointment of Sanofi Pasteur to begin the clinical development of a monovalent inactivated polio vaccine in Japan reinforces the government's commitment... 2011-06-07